Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison

Abstract

Nearly all patients with multiple myeloma eventually relapse or become refractory to treatment. Lenalidomide is increasingly administered in the frontline until disease progression or intolerance to therapy, resulting in the need for highly effective, lenalidomide-sparing options. In this study, carfilzomib plus daratumumab and dexamethasone were evaluated against lenalidomide-sparing, pomalidomide-containing triplets using matching-adjusted indirect comparison in the absence of head-to-head data. The analyses utilized long-term follow-up data from the CANDOR study (NCT03158688). Treatment with carfilzomib, daratumumab, and dexamethasone resulted in significantly longer progression-free survival (hazard ratio 0.60 [95% confidence interval: 0.37, 0.88])vs. pomalidomide plus bortezomib and dexamethasone, and numerically longer progression-free survival (hazard ratio 0.77 [95% confidence interval: 0.50, 1.08]) vs. daratumumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and previous lenalidomide exposure, the majority of whom were lenalidomide refractory. Carfilzomib plus daratumumab and dexamethasone offers a highly effective, lenalidomide-sparing treatment option for this population.

Keywords:

• Carfilzomib
• indirect treatment comparison
• lenalidomide-sparing
• progression-free survival
• relapsed/refractory multiple myeloma

Acknowledgements

The study was sponsored and funded by Amgen. The authors thank Hoora Moradian, PhD, and Colleen Dumont, BS, of Cytel, Inc. for methodological support and medical writing assistance in the preparation of this manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

Qualified researchers may request de-identified data from Amgen clinical studies. Complete details are available at the following: http://www.amgen.com/datasharing.

Additional information

Funding

This study was funded by Amgen. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this presentation, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.